Proxy Votes Now

Home › Funds › State Street › State Street SPDR S&P Biotech ETF

State Street SPDR S&P Biotech ETF (XBI) proxy voting record 2025-2026

Fund family: State Street · Filed by SPDR SERIES TRUST (CIK 1064642) · SEC series S000010018

Ticker: XBI (C000027706)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 495 with, 488 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 6 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with State Street as a whole

The same two figures as State Street’s manager page (773,265 ballot items across 134 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsState StreetItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)89.1%95389.7%592,191
Backed environmental and social shareholder proposals at US companiesn/a26.8%3,767

Where this fund voted differently from most State Street funds

Each ballot item this fund voted is set against the votes of the other State Street funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most State Street funds on all 896 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 96.1% of this fund’s 983 such votes could be given a sector; the other 38 (3.9%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care94547750.5%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections588286
Say-on-Pay15177
Audit-related14078
Compensation7438
Corporate Governance272
Capital Structure186
Extraordinary Transactions60
Environment or Climate11
Other Social Issues10
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Moderna, Inc.November 12, 2025$720M20
Moderna, Inc.May 6, 2026$557M52
Kodiak Sciences Inc.June 2, 2026$148M53
Halozyme Therapeutics, Inc.May 5, 2026$147M41
Revolution Medicines, Inc.June 18, 2026$146M43
Travere Therapeutics, Inc.May 19, 2026$144M146
Natera, Inc.June 11, 2026$141M83
Amgen Inc.May 19, 2026$140M155

Notable votes against management

MeetingCompanyProposalFundMgmt
May 6, 2026Moderna, Inc.To approve, on a non-binding, advisory basis, the compensation of our named executive officers.ForAgainst
May 6, 2026Moderna, Inc.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026.ForAgainst
June 2, 2026Kodiak Sciences Inc.Elect three Class II directors nominated by our board and named in this proxy statement: Bassil I. Dahiyat, Ph.D.ForAgainst
June 2, 2026Kodiak Sciences Inc.Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement.ForAgainst
May 5, 2026Halozyme Therapeutics, Inc.To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.ForAgainst
June 18, 2026Revolution Medicines, Inc.To elect two Class III directors to hold office until the 2029 Annual Meeting of Stockholders or until his successor is elected: Mark A. Goldsmith, M.D., Ph.D.ForAgainst
June 18, 2026Revolution Medicines, Inc.To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026; andForAgainst
May 19, 2026Travere Therapeutics, Inc.To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Roy BaynesForAgainst
May 19, 2026Travere Therapeutics, Inc.To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year. ELECTION OF DIRECTORS: Timothy CoughlinForAgainst
June 11, 2026Natera, Inc.To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this notice to serve as a Class I director until the annual meeting of stockholders held in 2028 and until his successor is duly elected and qualified. Class II Nominees: Jonathan SheenaForAgainst
June 11, 2026Natera, Inc.To ratify the appointment of Ernst & Young LLP as Natera, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.ForAgainst
May 19, 2026Amgen Inc.To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2027 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. BradwayForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

1,007 ballot items at 147 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, State Street SPDR S&P Biotech ETF (XBI) voted at 147 shareholder meetings of 144 companies, on 1,007 ballot items in all. Where management made a recommendation, the fund followed it on 50.4% of the items and voted against it 488 times. Its most frequent area of disagreement was director elections (286 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than State Street's funds as a whole (89.1% against 89.7%). It voted the same way as most State Street funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of State Street’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.